ICML 2023 | Insights into the ZUMA-23 trial: axi-cel in frontline high-risk LBCL
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the Phase III ZUMA-23 trial (NCT05605899), which is evaluating axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients with high-risk large B-cell lymphoma (LBCL) in the frontline setting. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
ZUMA-23 is a global Phase III randomized trial evaluating the potential of axicabtagene ciloleucel, axi-cel, in frontline patients with high-risk large B-cell lymphoma. The trial is now up and running and it’s going to enroll globally approximately 300 patients with IPI four and five, patients are eligible for the trial after they’ve had one cycle of R-chemotherapy. So patients are not untreated, but they’ve only had one cycle...
ZUMA-23 is a global Phase III randomized trial evaluating the potential of axicabtagene ciloleucel, axi-cel, in frontline patients with high-risk large B-cell lymphoma. The trial is now up and running and it’s going to enroll globally approximately 300 patients with IPI four and five, patients are eligible for the trial after they’ve had one cycle of R-chemotherapy. So patients are not untreated, but they’ve only had one cycle. And when they go on the study, they’re randomized one-to-one to either finish out the six cycles of R-chemotherapy, which includes R-CHOP and R-EPOCH, or to be randomized to axi-cel. And so this trial is eagerly anticipated to see what’s the potential of CAR-T cell therapy in the high-risk frontline patients.
Read more...
